<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Engineering Science</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/80C49C08-D611-4583-A18D-7EEB2EBD0BCB"><gtr:id>80C49C08-D611-4583-A18D-7EEB2EBD0BCB</gtr:id><gtr:firstName>Zhanfeng</gtr:firstName><gtr:surname>Cui</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD525772%2F1"><gtr:id>C1F3797A-1AA6-4F15-AC4F-0881B8A1588B</gtr:id><gtr:title>Development of perfused multiple micro-bioreactors (TissueFlux.TM)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D525772/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>We plan to carry out technical development work on the patented technology - perfused multiple microbioreactor systems to speed up its transfer to the commercial sector. Based on the concept developed and proved by a BBSRC project, we will develop necessary accessories including culture medium distributors and connectors and techniques for the surface treatment to the microbioreactors. We will also optimise the shape (according to the size) and size of the microbioreactors using CFD simulations to provide uniform hydrodynamic shear in the test section which is important for the study of cell and stem cell functions. The developed system can perform parallel and semi-high throughput experimentation for drug and toxicity testing with much improved reliability and reproducibility and can reduce the use of animals using 3D model tissue culture. During the project we will continue market research and prepare a business plan for the spin-off company.</gtr:technicalSummary><gtr:fund><gtr:end>2007-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>59841</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>A spin out company, Zyoxel Limited, was initiated following this project and finally launched in 2009 with 1M GBP investment.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>EAC02ACD-F331-4387-BE28-280E36B17C10</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56d73d50b53f36.12934910</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>we identified the industrial user needs and developed technology to meet their requirements. The key market is pharmaceutical industry and chemical industry, the main application was drug efficacy and chemical toxicity testing.</gtr:description><gtr:exploitationPathways>Commercialisation and spin out company.</gtr:exploitationPathways><gtr:id>5D999F03-B049-4E17-BD0D-DBD2927304AA</gtr:id><gtr:outcomeId>56d73cc8af0d58.14726704</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>CN BioInnovations Limited</gtr:companyName><gtr:description>CN BioInnovation Limited, formerly known as Zyoxel Limited, was established in 2009, with &amp;pound;1M investment. The company started to develop advanced three dimensional cell culture system (TissueFlex) and expand into drug discovery and testing.</gtr:description><gtr:id>8BD809A6-2C1A-4F39-ACA7-DC122F86A36C</gtr:id><gtr:impact>Employed about 12 people full time; accumulatively attracted about 4M GBP.</gtr:impact><gtr:outcomeId>56cf24ea6eb193.66560513</gtr:outcomeId><gtr:url>http://www.CN-bio.com</gtr:url><gtr:yearCompanyFormed>2009</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>16B8E2E1-115B-41DC-8E83-63C7FA44E547</gtr:id><gtr:title>A multi-paradigm modeling framework to simulate dynamic reciprocity in a bioreactor.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88325f5ad15e0a7fccad8bf4fbcc4986"><gtr:id>88325f5ad15e0a7fccad8bf4fbcc4986</gtr:id><gtr:otherNames>Kaul H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d4541a989db8.32169467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7389917F-E9A5-4841-96BA-562EE6F8AF28</gtr:id><gtr:title>Perfusion culture enhanced human endometrial stromal cell growth in alginate-multivalent integrin a5?1 ligand scaffolds.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a4e3979f177e6ad9e72d3a5c818988a"><gtr:id>5a4e3979f177e6ad9e72d3a5c818988a</gtr:id><gtr:otherNames>Li Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-3296</gtr:issn><gtr:outcomeId>56d4541abb5b79.18596428</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D525772/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>